DCHS2

DCHS2 is a member of the cadherin superfamily that acts as an atypical cadherin ligand for FAT-family cadherins to control planar tissue organization, growth, and cytoskeletal architecture across multiple developing organs (PMID:26116661, PMID:25340762, PMID:15003449). In the kidney, DCHS2 functions partially redundantly with DCHS1 and is bound by stromal FAT4 to restrict nephron progenitor self-renewal, acting independently of YAP in this context (PMID:26116661). During zebrafish craniofacial development, Dchs2 partners with Fat3 to drive polarized cell-cell intercalation and chondrocyte stacking, with its loss disrupting sox9a regulation (PMID:25340762). Beyond ligand functions, DCHS2 regulates the actin and microtubule cytoskeleton: loss causes bundled actin and microtubule networks and defective cortical granule exocytosis and cytoplasmic segregation, and its intracellular domain alone rescues microtubule bundling, defining a Fat-ligand-independent cytoskeletal role (PMID:26160902, PMID:40463075). In the heart, DCHS2 acts as a downstream effector of the lncRNA lncExACT1 through Hippo/YAP1 signaling to balance physiological versus pathological hypertrophy and cardiomyogenesis (PMID:35114812). DCHS2 is also required for normal hypothalamic-pituitary development, with mouse knockouts showing anterior pituitary hypoplasia (PMID:33108146).

1. 2004 Low

   Established DCHS2 as a distinct human cadherin superfamily gene, defining the molecular entity before any functional role was known.

   Evidence Protein motif search with gene-finding, PCR-based exon-intron verification, and tissue expression profiling (identified as CDH-J/PCDH-J)

   PMID:15003449

   Open questions at the time

   • Gene identification only, no functional assay
   • No interaction partners or pathway placement defined
   • No localization data
2. 2014 High

   Identified Dchs2 as a Fat3 ligand directing polarized chondrocyte intercalation, linking DCHS2 to planar cell polarity in craniofacial morphogenesis.

   Evidence Zebrafish dchs2 loss-of-function mutants, Fat3 binding assays, chimaeric analyses, and in vivo imaging of chondrocyte stacking

   PMID:25340762

   Open questions at the time

   • Mechanism connecting Fat3-Dchs2 binding to sox9a regulation not resolved
   • REREa interaction defined for Fat3, not directly for Dchs2 intracellular signaling
   • Mammalian conservation of this craniofacial role not tested here
3. 2014 Low

   Found recurrent DCHS2 frameshift mutations in MSI-H gastric and colorectal cancers, raising the possibility of cell-adhesion inactivation in tumorigenesis.

   Evidence SSCP and DNA sequencing of 89 gastric and 131 colorectal cancers stratified by MSI status

   PMID:24898286

   Open questions at the time

   • No functional validation that mutations inactivate DCHS2
   • Likely passenger versus driver status unresolved in MSI-H context
   • No phenotypic consequence demonstrated
4. 2015 High

   Demonstrated that DCHS2 acts redundantly with DCHS1 as a FAT4 ligand to restrict nephron progenitor self-renewal, and that this growth control is YAP-independent.

   Evidence Tissue-specific conditional deletions in mice, Six2/Fat4 double-mutant epistasis, electron microscopy, and gene expression analysis

   PMID:26116661

   Open questions at the time

   • Molecular signal downstream of FAT4-DCHS binding in progenitors unknown
   • Relative contribution of DCHS2 versus DCHS1 not separated
   • How a YAP-independent output is transduced not defined
5. 2015 High

   Revealed a Fat-ligand-independent function of DCHS2 in cytoskeletal organization, showing the intracellular domain alone suffices to control microtubule bundling.

   Evidence Maternal-zygotic dchs1b and dchs2 zebrafish mutants, live imaging, pharmacological phenocopy, and full-length versus intracellular-domain rescue constructs

   PMID:26160902

   Open questions at the time

   • Intracellular effectors mediating microtubule/actin regulation not identified
   • Link between cytoskeletal defect and Nodal signaling not mechanistically resolved
   • Distinct contribution of dchs2 versus dchs1b not separated
6. 2020 Medium

   Placed DCHS2 in hypothalamic-pituitary morphogenesis, showing knockout mice develop anterior pituitary hypoplasia despite normal cell-type commitment.

   Evidence Dchs2-/- mouse histological phenotyping, human pituitary expression analysis, and PSIS patient variant screening

   PMID:33108146

   Open questions at the time

   • Mechanism of hypoplasia (proliferation versus morphogenesis) not defined
   • FAT partner mediating pituitary role not established
   • Human variant causality not demonstrated
7. 2022 High

   Identified DCHS2 as a lncExACT1 downstream effector acting through Hippo/YAP1 to balance cardiac hypertrophy type and regeneration, extending its growth-control role to the heart.

   Evidence Zebrafish transgenic DCHS2 overexpression, cardiac-specific Cas9 knockin deletion in mice, AAV lncExACT1 manipulation, and promoter/binding assays

   PMID:35114812

   Open questions at the time

   • Direct molecular link from DCHS2 to YAP1 activation in cardiomyocytes not detailed
   • Whether cardiac role requires a FAT ligand unknown
   • Reconciliation with YAP-independent kidney function unresolved
8. 2025 Medium

   Defined a downstream effector of DCHS-family cytoskeletal regulation by placing dchs1b upstream of the intracellular-domain-binding protein ttc28 in microtubule control during epiboly, with dchs2 contributing redundantly.

   Evidence dchs triple loss-of-function zebrafish mutants, endogenous Dchs1b-GFP knock-in imaging, and dchs1b;ttc28 epistasis (preprint)

   PMID:40463075

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Direct DCHS2-TTC28 interaction not demonstrated (shown for Dchs1b)
   • How DCHS2 intracellular domain engages the microtubule machinery mechanistically unresolved

• How DCHS2 ligand-dependent FAT signaling and its ligand-independent intracellular cytoskeletal output are integrated within a single tissue remains unresolved.
• No structural model of DCHS2-FAT or DCHS2-effector binding
• Direct cytoskeletal effectors of the DCHS2 intracellular domain unidentified
• Mechanism reconciling YAP-dependent (cardiac) and YAP-independent (renal) growth control not established